The US FDA has given orphan status to Glassia from Israel’s Kamada, to treat Graft-versus-host-disease (GVHD).  Preliminary studies indicate that Glassia may be able to treat and reduce the severity of GVHD, a key life-threatening complication of stem cell transplantation from another person.

http://www.globes.co.il/en/article-kamada-awarded-fda-orphan-drug-status-for-gvhd-1000982117